Regeneron Pharmaceuticals Earnings per Diluted Share Trend

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

This module enables investors to look at Regeneron Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 311.7 M, Consolidated Income of 476.6 M or Cost of Revenue of 175.6 M, but also many exotic indicators such as Interest Coverage of 77.0381, Long Term Debt to Equity of 0.196 or Calculated Tax Rate of 10.7856. This module is a perfect complement to use when analyzing Regeneron Pharmaceuticals Valuation or Volatility. It can also complement various Regeneron Pharmaceuticals Technical models. Additionally take a look at analysis of Regeneron Pharmaceuticals Correlation with competitors.

Regeneron Pharmaceuticals Earnings per Diluted Share Marginal Breakdown

Showing smoothed Earnings per Diluted Share of Regeneron Pharmaceuticals with missing and latest data points interpolated. Earnings per diluted share as calculated and reported by the company. Approximates to the amount of [NetIncCmn] for the period per each [SharesWADil] after adjusting for [ShareFactor]..
View

18.00 

          10 Years Trend
Increasing
Slightly volatile
 Earnings per Diluted Share 
      Timeline 

Regeneron Pharmaceuticals Regression Statistics

Arithmetic Mean 5.92
Geometric Mean 4.19
Coefficient Of Variation 127.94
Mean Deviation 5.74
Median 5.52
Standard Deviation 7.58
Sample Variance 57.42
Range 23.74
R Value 0.89
Mean Square Error 13.28
R Squared 0.79
Significance 0.00011143
Slope 1.87
Total Sum of Squares 631.57

Regeneron Pharmaceuticals Earnings per Diluted Share Over Time

2017  10.34 
2018  21.29 
2019  18.00 

Other Fundumenentals of Regeneron Pharmaceuticals

Search macroaxis.com